Nathaniel Melling1, Ronald Simon2, Jakob R Izbicki1, Luigi M Terracciano3, Carsten Bokemeyer4, Guido Sauter2, Andreas H Marx2. 1. Department of Surgery, University Medical Center Hamburg-Eppendorf Hamburg 20246, Germany. 2. Institute of Pathology, University Medical Center Hamburg-Eppendorf Hamburg 20246, Germany. 3. Institute of Pathology, University Hospital Basel Basel 4031, Switzerland. 4. Department of Oncology and Hematology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf Hamburg 20246, Germany.
Abstract
PURPOSE: To investigate the significance of mammalian target of rapamycin (mTOR) in colorectal cancers. mTOR has recently been suggested as a prognostic biomarker and therapeutic target in an array of human cancers. FINDINGS: phospho-mTOR (p-mTOR) expression was analyzed by immunohistochemistry (IHC) on a tissue microarray containing 1800 colorectal cancers (CRC). Clinical follow-up data were available from all cancer patients. Positive p-mTOR immunostaining was seen in 83.5% of 1640 interpretable CRC and was considered weak in 862 (52.5%) and strong in 508 cases (31.0%). Matching clinico-pathological parameters were available in 1580 cases. p-mTOR staining was more frequent in tubular adenocarcinomas than in the less common histological subtypes (mucinous, medullary, signet cell; P=0.0163) and significantly linked to carcinomas of the left-sided colon and rectum as compared to right-sided CRC (P=0.0066). There was no significant association between p-mTOR expression and patients' gender, tumor stage, tumor grade or nodal status. In a survival analysis, p-mTOR IHC status of all CRC was unrelated to patient survival (P=0.702). In a multivariate analysis including pT, pN, tumor grade, tumor localization and p-mTOR expression, only pT, pN (both P<0.0001) and grade (P=0.0001) showed prognostic impact, but not tumor localization (P=0.9472) or p-mTOR expression (P=0.8879). CONCLUSION: Our observations indicate that p-mTOR overexpression is abundant in CRC and linked to left-sided tumor localization. The high frequency and overexpression of p-mTOR is providing further rationale for targeting this pathway therapeutically in CRC patients. However, a prognostic role of p-mTOR overexpression in CRC could not be confirmed.
PURPOSE: To investigate the significance of mammalian target of rapamycin (mTOR) in colorectal cancers. mTOR has recently been suggested as a prognostic biomarker and therapeutic target in an array of humancancers. FINDINGS: phospho-mTOR (p-mTOR) expression was analyzed by immunohistochemistry (IHC) on a tissue microarray containing 1800 colorectal cancers (CRC). Clinical follow-up data were available from all cancerpatients. Positive p-mTOR immunostaining was seen in 83.5% of 1640 interpretable CRC and was considered weak in 862 (52.5%) and strong in 508 cases (31.0%). Matching clinico-pathological parameters were available in 1580 cases. p-mTOR staining was more frequent in tubular adenocarcinomas than in the less common histological subtypes (mucinous, medullary, signet cell; P=0.0163) and significantly linked to carcinomas of the left-sided colon and rectum as compared to right-sided CRC (P=0.0066). There was no significant association between p-mTOR expression and patients' gender, tumor stage, tumor grade or nodal status. In a survival analysis, p-mTOR IHC status of all CRC was unrelated to patient survival (P=0.702). In a multivariate analysis including pT, pN, tumor grade, tumor localization and p-mTOR expression, only pT, pN (both P<0.0001) and grade (P=0.0001) showed prognostic impact, but not tumor localization (P=0.9472) or p-mTOR expression (P=0.8879). CONCLUSION: Our observations indicate that p-mTOR overexpression is abundant in CRC and linked to left-sided tumor localization. The high frequency and overexpression of p-mTOR is providing further rationale for targeting this pathway therapeutically in CRC patients. However, a prognostic role of p-mTOR overexpression in CRC could not be confirmed.
Authors: Kimmie Ng; Josep Tabernero; Jimmy Hwang; Emilio Bajetta; Sunil Sharma; Salvatore A Del Prete; Edward R Arrowsmith; David P Ryan; Michaela Sedova; Jin Jin; Kamel Malek; Charles S Fuchs Journal: Clin Cancer Res Date: 2013-06-06 Impact factor: 12.531
Authors: Anne O'Donnell; Sandrine Faivre; Howard A Burris; Daniel Rea; Vassiliki Papadimitrakopoulou; Nicholas Shand; Heidi A Lane; Katharine Hazell; Ulrike Zoellner; John M Kovarik; Cathryn Brock; Suzanne Jones; Eric Raymond; Ian Judson Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Josep Tabernero; Federico Rojo; Emiliano Calvo; Howard Burris; Ian Judson; Katharine Hazell; Erika Martinelli; Santiago Ramon y Cajal; Suzanne Jones; Laura Vidal; Nicholas Shand; Teresa Macarulla; Francisco Javier Ramos; Sasa Dimitrijevic; Ulrike Zoellner; Pui Tang; Michael Stumm; Heidi A Lane; David Lebwohl; José Baselga Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Allan J Pantuck; David B Seligson; Tobias Klatte; Hong Yu; John T Leppert; Laurence Moore; Timothy O'Toole; Jay Gibbons; Arie S Belldegrun; Robert A Figlin Journal: Cancer Date: 2007-06-01 Impact factor: 6.860
Authors: Andreas Marx; Philipp Simon; Ronald Simon; Martina Mirlacher; Jakob R Izbicki; Emre Yekebas; Jussuf T Kaifi; Luigi Terracciano; Guido Sauter Journal: Virchows Arch Date: 2008-08-19 Impact factor: 4.064
Authors: L Shayesteh; Y Lu; W L Kuo; R Baldocchi; T Godfrey; C Collins; D Pinkel; B Powell; G B Mills; J W Gray Journal: Nat Genet Date: 1999-01 Impact factor: 38.330
Authors: Satya Narayan; Asif Raza; Iqbal Mahmud; Nayeong Koo; Timothy J Garrett; Mary E Law; Brian K Law; Arun K Sharma Journal: iScience Date: 2022-06-03